Home・Aktien・Bio-Techne Corp

Bio-Techne Corp

Geschlossen

BrancheGesundheitswesen

72.79 0.17

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

72.75

Max

72.79

Schlüsselkennzahlen
By Trading Economics
Einkommen	3.6M 55M
Verkäufe	9.8M 321M
KGV Branchendurchschnitt	62.647 51.78
EPS	0.49
Dividendenrendite	0.44
Gewinnspanne	17.006
Angestellte	3,000
EBITDA	-6.7M 92M

Empfehlungen
By TipRanks
Empfehlungen	Sell
12-Monats-Prognose	+0.3% upside

Dividenden
By Acuity
Dividendenrendite Branchendurchschnitt	0.44% 1.96%
Nächstes Ergebnis	11. Nov. 2026
Nächste Dividendenausschüttung	23. Nov. 2026
Nächstes Ex-Dividendendatum	13. Nov. 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	176M 11B
Vorheriger Eröffnungskurs	72.62
Vorheriger Schlusskurs	72.79

Bio-Techne Corp Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Bio-Techne Corp Prognose

Kursziel

By TipRanks

0.3% Vorteil

12-Monats-Prognose

Durchschnitt 73 USD 0.3%

Hoch 73 USD

Tief 73 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Bio-Techne Corp – Dist angeboten haben.

Rating-Konsens

By TipRanks

Sell

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Bio-Techne Corp – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Bio-Techne Corp

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company has strategic partnership with ALZpath, Inc. to accelerate breakthroughs in neurodegenerative disease research and treatment, including Alzheimer's disease. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.